Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 09:05:09 11/07/2025 pm IST			5-day change	1st Jan Change
1,408.50 ^GBX	-3.16%		+0.25%	+4.60%

11/07	Sector Update: Health Care Stocks Slide Friday Afternoon	MT
11/07	FTSE 100 eases from record levels amid soft GDP	AN

Press Releases

GSK begins shipping influenza vaccine doses for the 2025-26 flu season	10/07	BU
GSK : Q2 2025 pre announcement aide memoire	09/07	PU
GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease	08/07	AQ
GSK : ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025	08/07	PU
GSK : Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5	25/06	PU
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis	24/06	BU
GSK : Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC)	23/06	PU
GSK : Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease.	20/06	PU
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US	16/06	BU
GSK : RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older	13/06	PU
GSK Plc - Director/PDMR Shareholding	12/06	PR
GSK : licenses Shigella vaccine candidate to Bharat Biotech for continued development	12/06	PU
GSK : data at ASCO and EHA showcase latest research and innovation across the oncology portfolio	29/05	PU
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee	28/05	AQ
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)	23/05	BU
GSK : Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)	22/05	PU
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis	09/05	BU
GSK : GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)	08/05	PU
GSK : continues to advance the future of respiratory medicine and patient care with new data at ATS	02/05	PU
GSK : Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine	01/05	PU
Glaxo: Q1 Earnings Snapshot	30/04	AQ
GSK : makes strong start to 2025 with growth in sales, profits and earnings	30/04	PU
GSK : Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma	17/04	PU
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices	17/04	BU
GSK : Arexvy recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices	17/04	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : Despite its challenges, GSK remains investable

May 21, 2025 at 07:38 pm IST

GSK CEO on US Expansion, M&A, Drug Pipeline, Trump

January 14, 2025 at 01:33 am IST

GSK plc : Back on track

May 03, 2024 at 02:47 pm IST